Shattuck Labs sees 14.7% drop in short interest in February

Got story updates? Submit your updates here. ›

Shattuck Labs, Inc. (NASDAQ:STTK), a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, saw a significant 14.7% decrease in short interest on its stock during the month of February. As of February 13th, there were 1,921,827 shares sold short, down from 2,251,778 shares at the end of January. The drop in short interest came as the company's average daily trading volume increased to 334,601 shares, resulting in a days-to-cover ratio of 5.7 days.

Why it matters

Changes in short interest can provide insights into investor sentiment and market expectations around a company's stock. The decrease in short interest for Shattuck Labs suggests that some investors may be becoming more bullish on the company's prospects, even as it continues to navigate the clinical development process for its immunotherapeutic vaccine programs.

The details

Shattuck Labs is a clinical-stage biotech company focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. The company employs a proprietary hapten-carrier conjugate technology designed to generate high-affinity drug-specific antibodies that can sequester target molecules in the bloodstream and reduce their passage across the blood-brain barrier.

• As of February 13th, 2026, Shattuck Labs had 1,921,827 shares sold short.
• This represents a 14.7% decrease from the 2,251,778 shares sold short as of January 29th, 2026.